

2031250PC.ST25_seq.txt
SEQUENCE LISTING

<110> Karyon Oy Ab
<120> Tumor targeting agents and uses thereof
<130> 2031250PC
<150> FI 20021762
<151> 2002-10-03
<160> 8
<170> PatentIn version 3.2
<210> 1
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> cysteine bridge

<400> 1

Cys Ile Arg Glu Cys
1 5

<210> 2
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> cynteine bridge

<400> 2

Cys Glu Arg Ile Cys
1 5

<210> 3
<211> 5
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> lactam bridge

2031250PC.ST25_seq.txt

<400> 3

Asp Ile Arg Glu Lys
1 5<210> 4
<211> 5
<212> PRT
<213> Artificial<220>
<223> synthetic<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> lactam bridge

<400> 4

Asp Glu Arg Ile Lys
1 5<210> 5
<211> 5
<212> PRT
<213> Artificial<220>
<223> synthetic

<400> 5

Ile Gln Leu Arg Asp
1 5<210> 6
<211> 10
<212> PRT
<213> Artificial<220>
<223> synthetic

<400> 6

Ile Gln Leu Arg Asp Trp Gly Phe Ile Leu
1 5 10<210> 7
<211> 5
<212> PRT
<213> Artificial<220>
<223> synthetic

<400> 7

Leu Arg Glu Leu Ser
1 5

2031250PC.ST25_seq.txt

<210> 8
<211> 10
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 8

Leu Arg Glu Leu Ser Met Gly Tyr Phe Lys
1 5 10